These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1206 related articles for article (PubMed ID: 11041459)

  • 1. Thyroid-stimulating antibody is related to Graves' ophthalmopathy, but thyrotropin-binding inhibitor immunoglobulin is related to hyperthyroidism in patients with Graves' disease.
    Noh JY; Hamada N; Inoue Y; Abe Y; Ito K; Ito K
    Thyroid; 2000 Sep; 10(9):809-13. PubMed ID: 11041459
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunoglobulins of untreated Graves' patients with or without thyrotropin receptor antibody (determined by porcine thyrocytes) universally elicit potent thyroid hormone-releasing activity in cultured human thyroid follicles.
    Sato K; Yamazaki K; Yamada E; Kanaji Y; Miura M; Obara T
    Thyroid; 1999 Oct; 9(10):979-88. PubMed ID: 10560951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
    Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
    Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The relationship between serum thyroid autoantibodies, iodine intake, development and prognosis of Graves' disease].
    Chen W; Man N; Li YS; Shan ZY; Teng WP
    Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):95-9. PubMed ID: 16624113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low response of the thyroid gland to endogenous thyrotropin increased by thyrotropin-releasing hormone in patients with euthyroid Graves' disease.
    Kashiwai T; Tada H; Watanabe Y; Shimaoka Y; Yagoro A; Hidaka Y; Fujikado T; Amino N
    Thyroid; 1998 Oct; 8(10):881-5. PubMed ID: 9827654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of TSH receptor antibody, thyroid stimulating antibody, and thyroid blocking antibody with clinical activity score and degree of severity of Graves ophthalmopathy.
    Subekti I; Boedisantoso A; Moeloek ND; Waspadji S; Mansyur M
    Acta Med Indones; 2012 Apr; 44(2):114-21. PubMed ID: 22745141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunoglobulins in children with Graves' disease.
    Shibayama K; Ohyama Y; Yokota Y; Ohtsu S; Takubo N; Matsuura N
    Endocr J; 2005 Oct; 52(5):505-10. PubMed ID: 16284425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Graves' ophthalmopathy in the absence of elevated free thyroxine and triiodothyronine levels: prevalence, natural history, and thyrotropin receptor antibody levels.
    Khoo DH; Eng PH; Ho SC; Tai ES; Morgenthaler NG; Seah LL; Fong KS; Chee SP; Choo CT; Aw SE
    Thyroid; 2000 Dec; 10(12):1093-100. PubMed ID: 11201855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of thyrotropin receptor antibodies in the development of hyperthyroidism: follow-up studies on nine patients with Graves' disease.
    Kasagi K; Tamai H; Morita T; Hidaka A; Hatabu H; Misaki T; Iida Y; Ishihara T; Ikekubo K; Kuma K
    J Clin Endocrinol Metab; 1989 Jun; 68(6):1189-94. PubMed ID: 2566620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences between changes in serum thyrotropin-binding inhibitory antibodies and thyroid-stimulating antibodies in the course of antithyroid drug therapy for Graves' disease.
    Yamano Y; Takamatsu J; Sakane S; Hirai K; Kuma K; Ohsawa N
    Thyroid; 1999 Aug; 9(8):769-73. PubMed ID: 10482368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of thyroid stimulating antibody in the diagnosis of thyroid associated ophthalmopathy of euthyroid patients.
    Kazuo K; Fujikado T; Ohmi G; Hosohata J; Tano Y
    Br J Ophthalmol; 1997 Dec; 81(12):1080-3. PubMed ID: 9497469
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of TSH receptor antibody by 'natural in vivo human assay' in neonates born to mothers with Graves' disease.
    Tamaki H; Amino N; Iwatani Y; Tachi J; Kimura M; Mitsuda N; Ichihara K; Tanizawa O; Miyai K
    Clin Endocrinol (Oxf); 1989 May; 30(5):493-503. PubMed ID: 2575017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on thyrotrophin receptor antibodies in patients with euthyroid Graves' disease.
    Kasagi K; Hatabu H; Tokuda Y; Iida Y; Endo K; Konishi J
    Clin Endocrinol (Oxf); 1988 Oct; 29(4):357-66. PubMed ID: 2908031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
    Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy.
    Gerding MN; van der Meer JW; Broenink M; Bakker O; Wiersinga WM; Prummel MF
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):267-71. PubMed ID: 10718823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serial changes in thyroid-stimulating antibody and thyrotropin binding inhibitor immunoglobulin at the time of postpartum occurrence of thyrotoxicosis in Graves' disease.
    Tamaki H; Amino N; Aozasa M; Mori M; Tanizawa O; Miyai K
    J Clin Endocrinol Metab; 1987 Aug; 65(2):324-30. PubMed ID: 2885336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationships between serum T3 index, thyroid volume, and thyroid stimulating, TSH receptor binding and thyroid growth stimulating antibodies in untreated Graves' disease.
    Bliddal H; Hegedüs L; Hansen JM; Bech K; van der Gaag R; Drexhage HA
    Clin Endocrinol (Oxf); 1987 Jul; 27(1):75-84. PubMed ID: 2888551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 61.